Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118905 · ClinicalTrials.gov registry record · Phase 4
Preserving Geriatric Muscle With an Osteoporosis Medication
A Phase 4 study of Osteoporosis, sponsored by Susan L. Greenspan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 155
- Enrollment target
- 1
- Study location
NCT06118905 is a Phase 4 study of Osteoporosis that is actively recruiting participants, run by Susan L. Greenspan. The registered enrollment target is 155 participants, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06118905, a Phase 4 study of Osteoporosis, is actively recruiting participants, sponsored by Susan L. Greenspan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
Conditions Studied
Interventions
- DRUG Denosumab 60 MG/ML
- DRUG Zoledronic Acid 5Mg/Bag 100Ml Infusion
Study Locations (1)
Pennsylvania
- St. Barnabas Woodlands - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06118905
The ClinicalTrials.gov registry entry for NCT06118905 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (90% lower). The listed sponsor is Susan L. Greenspan, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Denosumab 60 MG/ML is the first listed.
NCT06118905 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06118905 about?
NCT06118905 is a clinical study titled "Preserving Geriatric Muscle With an Osteoporosis Medication". Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
What is the current status of trial NCT06118905?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 155 participants. The study started on 2024-02-08. Estimated completion is 2029-03-31.
What conditions does trial NCT06118905 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT06118905?
The interventions under investigation include: Denosumab 60 MG/ML (DRUG), Zoledronic Acid 5Mg/Bag 100Ml Infusion (DRUG).
Who is sponsoring clinical trial NCT06118905?
This trial is sponsored by Susan L. Greenspan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118905 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Muscle Impact of Treating Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.